GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Thoratec Corp (FRA:TL1) » Definitions » Cyclically Adjusted FCF per Share

Thoratec (FRA:TL1) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Thoratec Cyclically Adjusted FCF per Share?

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Thoratec's adjusted free cash flow per share for the three months ended in Jun. 2015 was €0.322. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Jun. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-02), Thoratec's current stock price is €55.92. Thoratec's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2015 was €0.00. Thoratec's Cyclically Adjusted Price-to-FCF of today is .


Thoratec Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Thoratec's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thoratec Cyclically Adjusted FCF per Share Chart

Thoratec Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Thoratec Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Thoratec's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Thoratec's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thoratec's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Thoratec's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Thoratec's Cyclically Adjusted Price-to-FCF falls into.



Thoratec Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Thoratec's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2015 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2015 (Change)*Current CPI (Jun. 2015)
=0.322/100.6839*100.6839
=0.322

Current CPI (Jun. 2015) = 100.6839.

Thoratec Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200509 0.074 83.876 0.089
200512 0.098 83.032 0.119
200603 -0.313 84.298 -0.374
200606 0.103 85.606 0.121
200609 0.070 85.606 0.082
200612 0.005 85.142 0.006
200703 -0.086 86.640 -0.100
200706 0.021 87.906 0.024
200709 0.056 87.964 0.064
200712 0.093 88.616 0.106
200803 0.097 90.090 0.108
200806 0.068 92.320 0.074
200809 0.091 92.307 0.099
200812 0.201 88.697 0.228
200903 -0.031 89.744 -0.035
200906 0.168 91.003 0.186
200909 0.061 91.120 0.067
200912 0.232 91.111 0.256
201003 0.095 91.821 0.104
201006 0.219 91.962 0.240
201009 0.364 92.162 0.398
201012 0.150 92.474 0.163
201103 0.178 94.283 0.190
201106 0.255 95.235 0.270
201109 0.498 95.727 0.524
201112 0.294 95.213 0.311
201203 0.506 96.783 0.526
201206 0.414 96.819 0.431
201209 0.407 97.633 0.420
201212 0.345 96.871 0.359
201303 0.127 98.209 0.130
201306 0.271 98.518 0.277
201309 0.631 98.790 0.643
201312 0.271 98.326 0.277
201403 0.191 99.695 0.193
201406 0.260 100.560 0.260
201409 0.356 100.428 0.357
201412 0.312 99.070 0.317
201503 0.554 99.621 0.560
201506 0.322 100.684 0.322

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Thoratec  (FRA:TL1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Thoratec Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Thoratec's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Thoratec (FRA:TL1) Business Description

Traded in Other Exchanges
N/A
Address
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.

Thoratec (FRA:TL1) Headlines

No Headlines